price month
find path forward stop
initi coverag neutral rate tp
begun find way back pipelin execut failur
epacadostat need clinic evid trial execut
pipelin posit stock like jakafi franchis
revenu growth profil credit suiss compound-annual-growth-rate think
opportun fairli valu find difficult point specif pipelin asset
high convict clinic commerci perspect
rel smid-cap peer rate neutral think better
pipelin risk/reward commerci busi upsid elsewher
flow jakafi fairli valu think jakafi franchis
strong key driver revenu base cash-flow asset
fairli valu view data similar product itacitinib
compel opportun drug steroid-nav graft vs host
diseas gvhd modest
vari oncolog pipelin clinic data immatur rebuild
pipelin oncolog rel strong think mani asset
earli meaning valuat pemigatinib shown efficaci rare bile-duct
cancer opportun appear modest would compet
larger bladder cancer opportun
dermatolog franchis may better posit out-licens asset
topic ruxolitinib could effect treatment varieti immune-
mediat dermatolog condit think could out-licens
asset sell topic dermatolog drug differ vs oncolog
could unlock valu bolster oncology-focus pipelin
valuat risk valu share use sum-of the-part dcf
analysi result tp discount rate termin valu
growth rate risk commerci relianc jakafi clinic pipelin
failur bd regulatori external/market
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
incyt corp biopharmaceut compani engag
discoveri develop commerci proprietari
therapeut oncolog hematolog dermatolog
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky upsid case valuat base fda
approv ruxolitinib steroid-refractori gvhd itacitinib steroid-
nave gvhd pemigatinib cholangiocarcinoma within next
month also assum better expect jakafi
grey sky downsid valuat assum fda
approv ruxolitinib gvhd pemigatinib itacitinib grey sky also
assum neg data readout topic ruxolitinib vitiligo
atop dermat pemigatinib urotheli cancer also
assum jakafi revenu lower expect
 close
tabl content
guidanc consensu expect
jakafi growth upsid gvhd fairli valu
itacitinib steroid-nav gvhd drug modest
topic ruxolitinib interest dermatolog asset concern remain
pemigatinib cholangiocarcinoma urotheli cancer lag competit
olumi rheumatoid arthriti like face continu headwind us
current label
earli pipelin asset limit clinic data limit valu stock
cs peer relationship incyt
initi coverag neutral rate target price
commercial-stag mid-cap biotechnolog compani focus market develop
therapeut treat hematology/oncolog inflammation-rel diseas compani
revenu driven mostli jakafi commerci stage drug use treat myelofibrosi mf
polycythemia vera pv two rare blood cancer broadli refer myeloprolif
neoplasm beyond jakafi franchis also develop itacitinib similar drug
jakafi like approv diseas call graft vs host diseas gvhd pleas
see industri report detail larg cap biotech sector
also develop earlier-stag asset oncolog pemigatinib fgfr-mutat
tumor antibodi oral target drug capmatinib met inhibitor
beyond hematolog oncolog compani pursu develop topic form
jakafi refer topic ruxolitinib treat atop dermat vitiligo alopecia
follow late-stag failur epacadostat march share
recov mainli increment pipelin updat better-than-expect growth
jakafi itacitinib franchis
whole think share fairli valu given current
commerci busi jakafi iclusig royalti olumi avail
clinic data across pipelin posit incyt vari oncolog
pipelin indic core area watch throughout biopharma
enough clinic data high-valu tumor types/target
valuat dcf analysi support tp neutral rate
assum wacc weight averag cost capit fulli dilut share
tax rate wacc bloomberg consensu wacc
howev believ discount rate reflect risk futur cash flow incyt
year experi commerci jakafi view best-in-class
product current minim near-term competit threat assum lower
wacc confid abil market commerci jakafi
assum neg termin growth rate reflect view compani capabl
develop pipelin asset
risk upsid risk includ commerci risk better expect sale key
commerci asset clinic develop risk unexpect pipelin success across
early- mid-stag pipelin busi develop risk transform could
chang multipl otherwis posit impact share
downsid risk commerci risk wors expect sale key commerci asset
success challeng key patent signific portion compani
revenu base may risk clinic development risk late-stag pipelin failur
could neg impact share regulatori risk fda ema may delay fail approv
pipelin product commerci sale would impact futur cash flow
share valuat external/ market risk remain volatil sector
affect extern factor includ drug price legisl intellectu properti law
healthcar polici overal economi
jakafi like remain market leader growth price stock see jakafi
reach sale us across mf pv limit near-term
threat howev market matur expect growth rate jakafi declin
around could see gener competit forecast pv like gener
greater share revenu pv patient tend remain jakafi longer period
mf patient known durat therapi benefit label expans steroid-
refractori graft-versus-host diseas gvhd like huge driver sale
could produc increment think itacitinib steroid-nav
patient could larger opportun estim sale
quit blockbust decent contributor revenu base
vari pipelin earli assign meaning valu failur
epacadostat i/o melanoma clear setback compani
work rebuild pipelin recal trial demonstr addit benefit
metastat patient treat combin epacadostat pembrolizumab vs
pembrolizumab monotherapi result invalid prior hypothesi inhibit
enhanc benefit target think work pemigatinib
target fgfr-mutat tumor product howev ahead
recent approv balversa erdafitinib urotheli carcinoma incyt lead indic
cholangiocarcinoma rare cancer bile duct much smaller estim
patient address market world-wide ww europ japan life
beyond epacadostat rel challeng start see
pipelin progress mainli recent itacitinib updat
concern relianc jakafi drive revenu mani asset
focus highli competit space low patient popul look
pemigatinib think drug like effect fgfr-mutat bladder cancer
cholangiocarcinoma head start recent approv balversa
itacitinib demonstr posit data steroid-nav graft-versus-host diseas earli
trial howev think present modest commerci opportun
view dermatolog franchis best out-licens opportun
incyt ceo indic confer call consid option
dermatolog franchis includ keep hous find partner commerci
asset out-licens asset believ dermatolog franchis central
incyt oncolog focu success project franchis mainli topic
ruxolitinib atop dermat vitiligo alopecia could gener unadjust sale
could provid modest diversif product
revenu believ franchis would better suit out-licens product
would enabl focu develop next-gener novel oncolog asset
could success jakafi could use proce spin-off sale fund
develop expans oncology-focus pipelin
near-term outlook expect jakafi revenu continu support stock price
limit near-term threat short-term driver stock price center around potenti fda
approv ruxolitinib gvhd may top-lin data readout itacitinib ruxolitinib
catalyst could provid upsid short term valu
signific enough us re-rat share in-lin neutral rate
long-term outlook continu reli jakafi revenu long term
although pipelin asset could provid product diversif moder
optimist pipelin continu develop creat interest asset
although none like blockbust drug continu watch progress
pipelin could aggreg provid upsid stock diversifi
revenu away jakafi
credit suiss view incyt rel peer look profil vs
large-cap peer note three area differenti base busi project
grow near term better vs larger peer gilead
pipelin vari earli full confid could view
attract target either definit posit strength weak
jakafi revenu stream strong pipelin earli cash
minim debt could also buyer early-stag mid-stag compani
would assum someth oncolog field
charl martineau univers toronto guidanc consensu expect
provid
provid
line total revenu jakafi net product revenu estim within
guidanc consensu expect iclusig net product revenu estim in-lin
consensu forecast low end guidanc expens side
consensu expect within guidanc slightli consensu
basi incom includ royalti revenu jakafi olumi
whole think guidanc reason yet consensu expect
might high end short-term basi think forecast support
neutral rate within guidanc gener consensu expect
jakafi itacitinib expect opportun revenu upsid
jakafi well posit mf pv space like
upsid steroid-refractori gvhd acut chronic support
compel data itacitinib also well posit
take share steroid-nav gvhd popul data
trial also like posit two asset
drive near- long-term revenu allow
greater peak sale across two asset
despit initi success mf pv limit upsid exit
indic addit approv like steroid-
refractori gvhd opportun smaller compani
street expect itacitinib opportun also smaller
expect neg data updat either reach
gravita program could hurt long-term trajectori
jakafi itacitinib franchis
think jakafi solid drug like reach us peak sale across pv mf like approv s-r
gvhd yet think upsid fairli valu data compel steroid refractori acut gvhd like posit
data expect reach howev believ market like smaller expect steroid-
refractori patient steroid-nav patient itacitinib program
ii oncolog pipelinemultipl shot goal mani focu
follow phase failur epacadostat
rebuild oncolog pipelin novel high-valu asset
everyth pipelin success clinic
commerci point view success across key asset
enough diversifi compani portfolio drive
fgfr-mutat tumor capmatinib inhibitor develop
novarti nsclc could drive next leg growth
revenu growth asset pemigatinib
oncolog pipelin immatur unfocus
cholangiocarcinoma small indic face competit
 js recent fda approv fgfr inhibitor balversa
bladder cancer capmatinib show interest orr emso
asset control novarti get
limit econom addit nscl patient
mutat program includ lack novelti
area other limit success
begun rebuild clinical-stag pipelin follow failur epacadostat mani asset earlier
develop seen posit progress cours like pemigatinib note face
competit js balversa also like capmatinib inhibitor howev develop ultim econom control
novarti look pipelin like multipl shot goal think whole oncolog pipelin rel immatur
warrant higher valuat current assign
dermatologydiversif distract
given believ grow atop dermat market
unmet need vitiligo topic ruxolitinib uniqu approach
mild/moder ad vitiligo continu posit data
baricitinib ad could drive upsid end-us sale ultim
royalti dermatolog distract rather
pipelin diversif use alreadi discov
develop dermatolog asset distract incyt
 organ core oncolog focu
seen interest data topic ruxolitinib ad
success commerci asset safeti concern
surround baricitinib
approv anyth out-licens topic ruxolitinib
remain focus develop oncolog asset
capabl capac
ad even
think dermatolog franchis best posit out-licens opportun core compani current
oncolog focu anacor eucrisa sold premium think premium would current warrant
achiev believ baricitinib viabl ad asset given toxic emerg competit landscap ad
overal dermatolog borderlin distract could moder opportun right hand
ou novarti royalti
launch ww lilli royalti
ou novarti royalti
asia innov royalti
asia innov royalti
ww royalti paid
ww novarti royalti
result
asia
meet
figur catalyst month
phase data readout upcom medic meet
nda submiss novarti geometri
phase data present like esmo tripl
phase data present breeze-ad like eadv
dcf base case use discount rate fulli dilut share
wacc bloomberg consensu wacc howev
believ discount rate reflect risk futur cash flow
year experi commerci jakafi view best-in-class product
current minim near-term competit threat assum lower wacc
confid abil market commerci jakafi assum
neg termin growth rate compani capabl develop pipelin
asset see figur
incyt european commerci partner novarti establish track record
commerci execut minim risk associ jakafi/jakavi cash
flow assign termin growth free cash flow beyond forecast period
assum portfolio face patent challeng as-of-yet unknown competit
toward end forecast compani on-going invest
success replac revenu long term use dcf
calcul target price repres approxim discount
recent close price valuat assumpt reflect view jakafi/jakavi
best-in-class product support experienc commerci organ
minim competit threat temper uncertainti strategi beyond
increas /decreas wc
dilut share current price
probabl success po estim across coverag univers gener
appli follow po estim asset variou stage develop enter
phase enter phase enter phase asset
nda/bla stage rare diseas patient assign standard
probabl phase phase phase bla/nda
assumpt fda work close manufactur design
implement clinic program also adjust po estim base clinic data
phase compel phase neg yet compani move
pivot trial assum indic gvhd cholangiocarcinoma
urotheli cancer rare diseas sinc treatabl popul less
patient diseas increas po topic ruxolitinib
vitiligo announc posit phase data plan move forward
dcf sensit analys includ sensit analysi help support
valuat look differ wacc tvgr termin valu growth rate
figur dcf sensitivitywacc tvgr varianc
approv ruxolitinib steroid-refractori gvhd itacitinib steroid-nav gvhd
pemigatinib cholangiocarcinoma within next month also assum better-
than-expect jakafi revenu posit pipelin updat across early-stag portfolio
approv ruxolitinib gvhd pemigatinib itacitinib neg data
readout topic ruxolitinib vitiligo atop dermat well pemigatinib
urotheli cancer final scenario assum jakafi revenu lower
forecast
commerci risk better-than-expect sale estim consensu
expect jakafi mf pv iclusig olumi could drive share
clinic develop risk unexpect pipelin success posit
updat across early- mid-stag pipelin could posit affect share
busi develop risk current assum compani maintain
current level busi develop remain independ compani
sort transform either acquir acquir could posit
commerci risk sale jakafi olumi franchis key
contributor dcf valuat share sale wors
consensu expect could see share pressur unexpect
success competitor develop novel treatment mf pv gvhd ra
could also affect share jakafi revenu concentr also risk incyt
intellectu properti ip risk much revenu base reliant
strong patent protect ip gener manufactur success challeng
key patent signific portion compani revenu
base may risk loss major patent either us ou could
hurt incyt share price inabl challeng ip innov product could
hamper growth busi
clinic develop risk valuat base outcom
clinic trial late-stag asset shown clinic
ineffect unsaf would expect addit neg pressur share
regulatori risk food drug administr fda european medicin
agenc ema regulatori bodi approv requir
market sell therapeut delay outright reject approv
investig asset could neg impact futur cash flow
valu share fda ema could revok market
author market product due safeti efficaci concern
demonstr post-market set
external/market risk biotechnolog remain volatil sector
affect extern factor includ drug price legisl intellectu properti
law healthcar polici overal economi neg polici develop
and/or weaken economi could affect share price
jakafi growth upsid gvhd fairli valu
jakafi like remain leader myelofibrosi polycythemia vera
master marketjakafi like continu domin
appreci current valuat jakafi domin myelofibrosi mf
polycythemia vera pv market sinc fda approv link pi
respect jakafi market seven year see minor
sign market matur slow growth see seriou threat
jakafi domin near term due lack competit long patent life least
potenti extens remain high unmet need
indic celgene/bristol fedratinib mf fda pdufa potenti
risk like use patient refractori jakafi mf indic
near-term threat pv limit bristol/celgen seek pv
indic fedratinib despit believ healthi market strong
revenu base think cash flow jakafi well appreci current
stock price key neutral rate share
estim in-lin current consensu expect project end-
user sale in-lin consensu forecast us compound-annual-growth-rate ou
compound-annual-growth-rate see figur view vs consensu
continu expect jakafi drive us top-lin sale
dcf basi jakafi us sale royalti gener bulk per-shar
valuat view label expans graft-versus-host diseas gvhd repres
modest per-shar dcf jakafi believ well appreci current
stock price note itacitinib steroid-nav gvhd like repres larger
opportun vs jakafi discuss opportun next section
potenti risk mf competitor unlik take share jakafi sale jakafi
remain approv treatment mf current indic intermedi
high-risk mf includ primari mf post-pv mf post-essenti thrombocythemia
mf number competitor gilead former asset momelotinib fail
develop safe effect altern jakafi believ competitor like
posit drug second-lin set mf rather compet directli
jakafi front-lin set view latest-stag competitor class
celgene/bristol fedratinib jak inhibitor repres materi risk
like use patient fail jakafi figur state
fedratinib could compet directli compani benefit feel unlik
head-to-head trial jakafi perform henc see fedratinib
use addit potenti risk fedratinib mitig mf
indic vs pv becom smaller share jakafi revenu highlight
mf share revenu mf grow slower rate pv due longer durat
pv therapi
competitor space appear face difficulti figur cti
european market
author applic februari meanwhil bristol-my squibb chose
acquir outstand share promedior phase anti-fibros agent
event highlight drug could lose momentum unlik compet
front-lin set
european mf
cont develop
us clinic hold
exercis warrant
limit near-term risk pv market jakafi like maintain domin
hydroxyurea-refractori pv market roch idasanutlin earli stage unlik
repres signific near-term threat figur posit ahead jakafi
would like requir head-to-head phase trial ropeginterferon repres even
small risk drug posit front-lin pv vs hydroxyurea front-lin therapi
like still follow jakafi whether hydroxyurea interferon use
jakafi revenu concentr repres longer-tern risk look
fundament long-term somewhat concern revenu
depend jakafi jakafi clear growth driver relianc one asset
seen higher-risk long term especi gener manufactur challeng
ip earlier expect current around posit asset near-term
believ sale franchis drive top bottom-lin growth
howev would like see revenu diversif comfort stock
jakafi benefit think upcom like approv fedratinib impact
sale jakafi fedratinib like use jakafi failur focus
long-term durabl franchis note much termin valu predic
exclus abil maintain franchis expect see
modest diversif sale topic ruxolitinib pemigatinib itacitinib
jakafi growth like slow mf pv market matur project smaller us
jakafi mf pv sale growth futur year market matur model includ
us mf pv sale grow see figur in-
line consensu expect project adjust sale
jakafi gvhd conserv view opportun state
sale gvhd includ guidanc feel aggress
consid product still review treatabl popul small
royalti ex-u sale jakavi novarti licens sell ruxolitinib outsid
us expect grow compound-annual-growth-rate consensu in-lin
view see figur novarti pay royalti jakavi sale base
novarti sale royalti report project royalti in-lin slightli
consensu toward note minor contributor
valuat product
pv indic account greater share futur jakafi sale rel mf
current breakdown per jakafi sale mf versu pv
manag highlight rel ratio pv sale grow faster rate
trend compani seen sever year grow share mainli attribut
longer durat therapi patient take jakafi pv take five year
per compani suggest pv could larger market mf
futur trend reflect model compound-annual-growth-rate pv vs mf
figur project jakafi end-us sale
figur project us patient jakafi
long patent life potenti extens jakafi expect
exclus anoth eight year us composit matter patent
expir potenti patent extens
assum approxim five year peg loe earli receiv
letter indic abbrevi new drug applic anda file purport
challeng patent could risk long-term sale franchis
expans strategi includ effort way data expect produc
new novel formul would alter jakafi pk profil improv anemia
would effect permit re-pat drug extend exclus beyond
late part expans strategi test combin
jakafi look inhibit administ jakafi mf addit
data expect
label expans steroid-refractori graft-versus-host diseas
current stock price unlik drive
signific upsid small treatabl popul
potenti approv ruxolitinib gvhd current seek
approv use ruxolitinib patient develop gvhd follow allogen hematopoiet
stem cell transplant hsct inadequ respons steroid therapi
snda supplement new drug applic current fda review
pdufa date februari fda delay pdufa date three month
request addit data recal seek approv steroid-
refractori sr acut gvhd patient use reach phase trial phase
trial reach current way compar ruxolitinib best avail
therapi sr acut chronic gvhd data expect posit reach
sr chronic gvhd could expand indic sr chronic popul
limit opportun jakafi gvhd given small treatabl popul label
expans like price share view opportun steroid-refractori
gvhd acut chronic rel limit owe believ small
treatabl popul amount dcf valuat compani
estim total treatabl popul steroid-refractori acut chronic gvhd
us ou estim treatabl popul lower
us ou even use higher estim treatabl popul remain
small largest subset patient outsid us receiv
royalti payment vs full econom us
steroid-refractori gvhd unlik chang treatment
paradigm current seek approv jakafi patient gvhd
refractori fail steroid treatment highlight mainstay gvhd
treatment mani decad steroid methylprednisolon given
issu steroid bone loss decreas immun hormon imbal think
incyt asset itacitinib could well posit steroid-nav gvhd
popul discuss next report cautiou jakafi steroid-
nave patient believ approv significantli alter treatment
landscap ultim drug may given graft alreadi like fail
particularli acut set ruxolitinib may better suit chronic gvhd
addit expect payer pushback reimburs could limit initi uptak
highlight mani drug mycophenol mofetil etanercept
sirolimu etc use combin treat sr-gvhd clear
consensu exist physician option steroid failur think jakafi
take share absent compel clinic data think
go-to asset set larger opportun remain steroid-nav gvhd
itacitinib could take signific share steroid refractori set think
mani option rel small patient pool
modest efficaci small trial primari endpoint phase studi
evalu ruxolitinib combin corticosteroid sr acut gvhd met
primari endpoint demonstr day overal respons rate orr
patient see figur trial also met secondari endpoint highlight
figur data posit trial small single-arm studi
abl file use data trail expect addit data
trial remaind potenti
data set could help us better understand usag vs best avail therapi
acut chronic set see figur
figur reach sr acut gvhdefficaci
durat respons day respond
median durat respons day ci
figur reach sr acut gvhdsafeti
signific surpris safeti anemia common ae similar prior trial
jakafi mf pv anemia common advers event reach
trial see figur thrombocytopenia neutropenia also
common particularli patient higher grade gvhd would expect
hematolog abnorm common jakafi trial investig mf
pv patient therefor unexpect see similar major
advers event drug reason toler
figur reach reach design
orr month
itacitinib steroid-nav gvhd drug modest
itacitinib could provid sale diversif unlik blockbust drug
potenti sale itacitinib inhibitor current
evalu steroid-nav sn gvhd think asset could help diversifi incyt
revenu base expand area compani alreadi emerg leader
gvhd see itacitinib greater opportun compar jakafi think sn
popul larger clinic profil asset seem compel review
later section think end-us market produc blockbust
sale given rel cost corticosteroid think could payer
push back usag novel therapeut front-lin therapi even posit evid
clinic trial payer previous slow chang coverag sever year
evid avail across therapeut area indic consequenti forecast
modest updat payer coverag near-term could limit uptak could see
acceler itacitinib shown outright superior steroid monotherapi much
posit view itacitinib predic continu posit data on-going gravitas-
current trade level fairli valu itacitinib opportun forecast
revenu vs consensu slightli consensu sale
expect vs see figur believ payer headwind
could potenti limit sale pushback cover itacitinib corticosteroid
efficaci risk-adjust basi itacitinib contribut
dcf valuat share consensu expect slightli ahead
estim think delta small suggest asset fairli valu
compar jakafi sr-gvhd think sn repres larger
opportun view market significantli larger steroid-nav
front-lin gvhd compar steroid-refractori gvhd incyt estim
estim gener in-lin research world-wide acut
chronic compar market steroid refractori us ex-
us henc opportun significantli larger steroid-nav sn gvhd market
charl martineau univers toronto figur incyt estim market steroid-nav gvhd
despit larger market sn gvhd feel opportun project
blockbust drug akin jakafi speak doctor
research space steroid still reason option patient gvhd
think could limit usag newli diagnos patient gvhd
treat itacitinib compar launch jakafi highlight
effect medic mf prior jakafi henc uptak curv jakafi
mf strong option expect itacitinib sn-fvhd
temper current avail treatment option
total number patient receiv allogen hsct
approxim us assum approxim growth base
histor trend see figur figur sn-gvhd market model
assum approxim allogen hsct patient gvhd
develop chronic form base academ literatur add approxim
hsct patient develop gvhd de novo stem thought
acut case look durat therapi itacitinib assum approxim
patient given year still therapi year two owe chronic natur
diseas assum approxim patient therapi increas
us assum pariti price jakafi approxim per month
gross-to-net discount complianc assum modest gross price
increas annual launch outsid us assum discount launch
price annual price increas complianc
number patient receiv allogen hsct
incid gvhd hsct
number patient hsct develop agvhd
patient develop cgvhd
number cgvhd patient elig jakafi
number patient take itacitinib agvhd
averag durat therapi month acut gvhd
patient month treatment acut gvhd
patient continu treatment
patient cont treatment chronic gvhd
patient treat chronic gvhd
averag durat therapi month chronic gvhd
patient month treatment chronic gvhd
total month treatment itacitinib gvhd
gross net discount
us sale itacitinib gvhd million
number patient receiv allogen hsct
incid gvhd hsct
number patient hsct develop agvhd
patient develop cgvhd
number cgvhd patient elig jakafi
number patient take itacitinib
averag durat therapi month acut gvhd
patient month treatment acut gvhd
patient continu treatment
patient cont treatment chronic gvhd
patient treat chronic gvhd
averag durat therapi month chronic gvhd
patient month treatment chronic gvhd
total month treatment itacitinib gvhd
discount us gross price
gross net discount
us estim potenti launch later initi phase data
expect top-lin data first trial expect
back half depend time could see full data present
decemb acut sn-gvhd second trial grivata
pivot program phase chronic sn gvhd current enrol
patient could see data although yet confirm
follow potenti approv estim later expect rel seamless
launch alreadi infrastructur sell gvhd drug jakafi
also alreadi relationship physician treat gvhd due market jakafi
mf pv highlight specialist involv hsct treat mf gvhd
forecast unadjust sale us addit ou
see figur figur purpos valuat appli po
factor cf itacitinib
ou sale itacitinib gvhd million
posit proof-of-concept data itacitinib orr front-lin
treatment set acut gvhd proof-of-concept data itacitinib steroid-
nave acut gvhd compel studi patient show
overal respons rate patient complet respons see figur
orr high difficult us determin much impact steroid
view phase studi tell sinc compar itacitinib
steroid placebo steroid interestingli overal result better steroid-
nave patient suggest itacitinib may benefici
charl martineau univers toronto figur proof-of-concept data steroid-nav acut gvhd
phase trial like whole stori gravita trial data expect
phase trial current on-going provid clariti potenti
benefit itacitinib dual-arm studi larg trial
compar itacitinib steroid placebo steroid acut popul see
figur treatment arm except primari endpoint
measur month vs day design similar ruxolitinib phase trial
reach gvhd state data present
although specif time given enrol
patient expect commenc year top-lin data
orr month
put togethergreat opportun jakafi gvhd around
compel evid present phase trial would
expect itacitinib reach peak sale could help diversifi incyt
revenu howev like multibillion dollar drug like jakafi mf pv
believ gvhd market significantli smaller current front-lin treatment
steroid efficaci patient contrast mf option
extrem limit look gvhd whole steroid-nav steroid-
refractori popul itacitinib larger opportun vs jakafi gvhd note
ww commerci right itacitinib help direct econom
compani vs ou jakavi commerci novarti also
believ potenti launch like expedit quickli synergi
jakafi mf pv addit sr-gvhd launch await releas top-lin
data get full pictur
concern remain around within incyt
topic ruxolitinib atop dermat vitiligo could promis
indic howev question program fit within incyt
mechanist point view topic ruxolitinib make sens atop dermat
vitiligo support mid-stag clinic data indic howev note
atop dermat like becom crowd indic follow launch
pfizer eucrisa regeneron/sanofi dupix option like
approv come year think asset could better suit
dermatologic-focus compani either directli spun sold effect
commerci would requir invest heavili dermatology-focus
salesforc akin primari care product vs special oncolog
product acknowledg earn call compani analyz
benefit spin-off commerci drug in-hous still appeal
review mechanist rational clinic data potenti sale indic
analyz npv spin-off could look like topic ruxolitinib
remain in-hous estim sale assum probabl
success valu asset approxim estim incyt
could sell asset assum program appli
premium base recent take-out premium observ space
could attract way rais capit expand oncolog pipelin
vitiligoto driven jak-medi inf- inflamm ultim caus
damag melanocyt result hypo-pig skin spot oxid stress
factor trigger releas skin cell recruit cell
site inflammatori activ caus damag ultim loss epiderm
melanocyt result develop white macul skin white spot
visibl seen patient condit see figur thought inhibit
topic format cycl inflamm stop allow
melanocyt regener restor pigment skin topic applic
drug allow target applic therapi inflamm occur without
risk system applic
charl martineau univers toronto figur biolog mechan vitiligo
initi clinic data suggest efficaci patient vitiligo open-
label poc trial cream appli bid saw follow
improv mean vasi vitiligo area sever index score
improv facial vasi score
figur detail
accord safeti profil seem accept common
erythema hyperpigment transient acn
figur proof-of-concept evid topic ruxolitinib vitiligo
phase poc data support progress on-going phase random
double-blind studi recent announc data phase proof-of-
concept trial posit plan move forward phase trial
compani plan present full phase data upcom medic meet
detail still announc figur trial design
clinicaltri gov entri data inform phase trial like requir
registr could get addit detail phase trial design time later
assum phase begin could see clinic data set
potenti approv
given high-unmet need vitiligo limit effect treatment option
believ could larg opportun approv regul us
vitiligo foundat estim peopl may affect us
activ see treatment could increas effect topic option
asid cosmet disfigur patient also experi significantli impair
qualiti life due depress anxieti research note despit current
treatment exclud topic ruxolitinib diseas highli unpredict cours
way estim potenti skin re-pigment sentiment echo
physician spoke indic
here noth label vitiligo think steroid dont realli work
particularli well patient think applic topic ruxolitinib
promis
model suggest approv could gener
think could captur reason portion patient note
payer may will fulli cover treatment argument could made
cosmet therapi figur market model despit posit open-
label data need see blind data patient posit asset
model
charl martineau univers toronto figur topic ruxolitinib vitiligo market model
patient million unless note
us popul year older
preval vitiligo
number patient vitiligo
patient pigment involv bodi
number patient elig topic therapi
patient control topic corticosteroid
number patient control corticosteroid
number patient elig ruxolitinib
number patient take ruxolitinib round
gross net discount
us sale ruxolitinib vitiligo million
topic ruxolitinib atop dermat understand biolog rational
howev concern market ad becom increasingli
crowd data phase trial topic ruxolitinib ad posit mild-to-
moder patient statist signific improv vs placebo vehicl cream
patient mild-to-moder ad comparison topic steroid less favor see
figur note steroid compar phase trial also perform well
case better dose topic ruxolitinib think topic ruxolitinib
superior topic steroid phase support wide-spread use
success commerci think sell dermatologist might difficult
product efficaci topic steroid safeti accept
grade treatment-rel see figur
figur phase efficaci data topic ruxolitinib ad
mean improv easi
score baselin week
mean improv easi
score baselin week
proport iga
proport iga
figur phase safeti data topic ruxolitinib ad
phase data move forward two phase trial
data expect earli examin phase design ad
trial would like see comparison topic steroid think superior
standard care could provid much compel argument use ad patient
believ topic ruxolitinib superior placebo vehicl evidenc
phase absent comparison data standard care p-valu
unconvinc substanti commerci market trial
entri trial entri
given pivot data lack comparison standard care mild-to-
moder patient think uptak slow could limit
seen anem sale pfizer eucrisa anoth novel topic therapi mild-to-moder
ad one chief complaint surround use eucrisa burn sensat
appli given like caus vehicl cream could also see
issu patient use topic ruxolitinib view believ greatest
opportun ad remain moderate-to-sever patient treat dupix
system immunomodul agent less mild-to-moder patient
given potenti headwind forecast late peak sale
figur topic ruxolitinib ad market model
patient million unless note
us popul year older
preval ad
number patient ad
mild moder
number patient mild moder ad
patient control topic therapi
number patient control topic therapi
number patient elig ruxolitinib
number patient take ruxolitinib round
gross net discount
us sale ruxolitinib ad million
use base-cas forecast would estim spin
dermatolog busi topic ruxolitinib could valu
assum po low end appli premium high-end base
recent take-out premium observ space think
would better spin asset given need build commerci forc
synergist current hematology-oncology-focus forc outright
sale licens asset could allow focus invest
oncolog busi align broader critic
enough focu develop commerci asset within compani core
compet hematology-oncolog pure dermatolog play topic ruxolitinib
seem like distract incyt engin
evalu
pemigatinib cholangiocarcinoma urotheli
cancer lag competit small market
pemigatinib like modest opportun estim must
directli compet js recent approv balversa like drug
think recent clinic data compel see outsiz potenti sale
think olumi could contribut royalti revenu vs end-us
sale pemigatinib valuat pemigatinib small contributor dcf
analysi share approxim across cholangiocarcinoma
urotheli cancer
pemigatinib pemigatinib inhibitor fibroblast growth factor receptor fgfr
isoform
metastatic/unresect
cholangiocarcinoma cca urotheli cancer uc pemigatinib benefit posit
phase data high unmet need abil leverag drug multipl indic
howev js balversa erdafitinib pi link could pose signific headwind
first-mov advantag uc recent approv fda april
addit could challeng incorpor fgfr test clinic aid diagnosi
current routin perform despit headwind believ fda approv
like cca po base progression-fre surviv month
compar month chemotherapi standard care potenti expans
uc significantli larger indic
forecast in-lin consensu see reason
ahead street estim figur detail highlight major
pemigatinib revenu toward beyond attribut growth uc
pemigatinib cca provid modest cash flow indic approv
could add signific upsid includ estim clinic data
avail posit data present pemigatinib could take greater
share market believ expans cca set could add
much peak revenu could signific upsid driver
share potenti ad addit dcf analysi compani
potenti first-to-market advantag js balversa could provid signific head
start ahead pemigatinib uc jnj/janssen recent fda-approv
balversa erdafitinib also fgfr inhibitor use metastat unresect uc
initi treatment chemotherapi launch on-going year head start
pemigatinib phase trial uc modifi includ
continu dose regimen initi start intermitt dose see figur
trial design start intermitt switch continu use erdafitinib
phase trial chang result increas respons rate
continu dose regimen erdafitinib believ like make sens
perform addit studi ensur data optim howev result delay
like give addit head start
figur trial modif includ continu dose regimen
compel data cca primari endpoint orr
transloc phase studi pemigatinib cca demonstr
promis data unresect metastat cca patient previous underw
chemotherapi patient transloc cohort demonstr orr
partial respons stabl diseas median month see
figur note transloc commonli found patient cca
key point includ combin diseas control rate dcr data
highli compel consid median cohort month vs
standard chemotherapi
major safeti issu pemigatinib gener toler
major seriou advers event ae common see figur
hyperphosphatemia alopecia diarrhea decreas appetit
patient fatal outcom although relat
interim data highlight modest efficaci continu dose regimen
potenti increas respons interim data releas
trial larg posit best orr cohort
transloc although includ unconfirm respons see figur
highlight common isoform found uc addit waterfal
plot demonstr posit trend toward decreas target lesion baselin
feel good step toward prove efficaci uc howev await full trial
result includ modifi design includ continu dose would expect
continu increas efficaci could potenti increas side effect
studi cca initi modifi uc data
expect expect file nda base phase
trial cholangiocarcinoma see figur phase trial
target cholangiocarcinoma current enrol patient expect
commenc later year urotheli cancer phase trial
underw trial modif expect present data also
plan studi pemigatinib indic includ tumor-agnost set
trial begin
week
cohort
orr
orr fgfr alter
week week
cohort fgfr
orr
orr fgfr alter
recruit continu cohort
fgfr inhibit repres signific opportun explor therapi
fibroblast growth factor fgf involv broad rang function includ
embryogenesi inflamm wound heal angiogenesi tissu homeostasi
widespread function surpris mutat fgfr associ
host cancer urotheli endometri breast lung cancer squamou ovarian
fgfr mutat also somewhat common occur solid tumor
patani et al broad array cancer associ fgfr make great target
studi knowledg could leverag fight multipl indic furthermor
precis fgfr isoform test get right point target therapi promis
individu regimen could potenti result better efficaci less wait
part tyrosin kinas signal pathway fgfr thought play
oncogenesi via gene amplif activ mutat
transloc role fgfr isoform highlight figur
exampl fgfr isoform result activ transloc fgfr
caus activ mutat overlap role isoform caus cancer
overal four isoform becom activ via multipl mechan amplif
mutat transloc etc fgfr dimer upon ligand bind cell
surfac trigger downstream pathway mapk stat result dna
charl martineau univers toronto figur fgfroncogen driver cancer
fgfr isoform creat equal pre-clin data pemigatinib highlight
relev isoform pre-clin evid gener suggest differ
fgfr mutat react uniformli across cancer type mean mutat
specif isoform relat particular type cancer henc inhibit
uc may benefici inhibit cca may effect
demonstr inhibit show efficaci fgfr
aberr show signific result addit similar effect observ
uc
look pemigatinib preclin data see certain fgfr isoform
central tumor reduct see figur inhibit mpn show
greater reduct tumor volum inhibit display dose-rel reduct
cca show similar effect bladder cancer uc three model
highlight relationship specif isoform certain cancer
leverag pemigatinib indic tumor-agnost strategi interest
await data owe mani tumor type associ fgfr aberr
pemigatinib potenti leverag mani indic one area
alreadi process develop tumor-agnost popul drug
target gener cancer rather specif tissu alreadi drug
market approv popul lilly/loxo vitrakvi larotrectinib approv
patient neutrophil receptor tyrosin kinas ntrk gene fusion rather
target specif anatom site kidney renal cell carcinoma vitrakvi target
ntrk mutat could present number cancer colorect thyroid
lung etc pemigatinib could theoret tri similar manner fgfr
aberr suggest market patient
success could signific opportun howev await clinic data
rais convict expect initi trial
earli revenu cca uc main long-term driver earli sale figur
driven pemigatinib cca approv uc project sale surpass
cca mainli due larger address market uc ww patient vs
cca would expect significantli larger revenu cca ultim
approv cca greater market penetr total sum
pemigatinib sale would result share uc vs cca see
figur model assum launch us cca indic
launch ex-u forecast potenti us launch uc us vs ex-
us launch includ cca model addit data present
charl martineau univers toronto figur pemigatinib bladder cancer main driver franchis
pemigatinib long-term sale mix tumor type
pemigatinib promis leverag larger indic believ
fgfr inhibitor possess signific potenti base pre-clin incyt phase
trial pemigatinib may bright spot less-than-compel early-stag pipelin
drug shown posit data cca uc like drug gain
approv cca could provid modest cash flow howev real driver
expand indic larger popul urotheli tumor agnost breast
endometri cca would also larg market far data compel still
rel limit size scope look forward see pemigatinib
stori unfold drug next month data releas
olumi rheumatoid arthriti like face
continu headwind us current label
olumi baricitinib anoth inhibitor indic treatment
moderate-to-sever rheumatoid arthriti ra receiv royalti world-wide sale
olumi lilli retain ww right olumi dealt seriou blow fda
approv lower mg dose follow complet respons letter april
refil mix fda panel fda approv higher efficaci
dose owe safeti concern increas risk infect thrombosi note
clinic trial link nejm articl compar head-to-head humira
adalimumab given import us market launch tepid
disappoint sale like led decis end addit co-fund
olumi develop lilli discuss later dcf-basi estim
royalti product contribut dcf analysi compani
insignific nowher near import jakafi
steadi revenu mostli lost opportun us
royalti given headwind end-us sale estim olumi
consensu expect sale forecast vs consensu
expect also highlight like launch next-gener jak inhibitor
like better profil vs olumi xeljanz model assum
royalti increas base sale mileston despit
headwind us see growth come ou sale higher dose
approv approxim ww sale
figur olumi project royalti incyt
incyt decis discontinu fund olumi posit strateg move
view earn call announc would stop fund
olumi lilli compani believ substanti increment royalti rate
earn ra agre support compani decis move forward
compani plan realloc capit project throughout
believ strateg use cash flow view potenti upsid
olumi enough warrant invest still entitl
base-ti royalti lilli expect grow proport net olumi
sale howev increment royalti expect declin rel lilli
addit development cost ra
olumi pi reviewthrombosi infect limit approv efficaci
mg dose us mg daili approv olumi pi link fda
hesit safeti concern present phase trial taylor et al trial
compar placebo mg baricitinib mg adalimumab week patient
ra inadequ respons methotrex studi found signific
clinic improv baricitinib compar placebo adalimumab howev safeti
data show signific differ platelet count week baricitinib show
increas platelet vs decreas adalimumab placebo see figur
compani data new england journal medicin
thrombocytosi demonstr trial concern thromboembol caus
fda deni mg dose baricitinib includ black box warn pi
see figur addit black box warn highlight baricitinib could result
higher rate infect base trial data rate infect
adalimumab baricitinib similar see figur nevertheless feel
without mg dose label drastic limit usabl baricitinib ra
lilli work remov black warn success unlik lilli state
attempt packag real-world data includ mg dose outsid us
evid us approv compani current talk fda
possibl get mg dose approv potenti updat pi remov
black box warn howev given larg bodi efficaci safeti data think full
approv without warn highli unlik note fda previous
remov black box warn post-market data salmeterol howev
rare occurr lilli given indic substant progress
crowd space make ra tough market olumi competit ra market
still market ra highli competit biolog like humira
adalimumab enbrel etanercept remicad infliximab tnf-alpha inhibitor
best-sel drug market biosimilar mani
product launch front-lin market get even crowd furthermor
ad jak inhibitor market increas competit given current pi
hard us imagin scenario olumi gain signific share
second-lin market approv jak inhibitor pfizer xeljanz ra
approv effect dose see figur upcom competitor space
includ upadacitinib pdufa galapagos/gilead filgotinib
phase could potenti disrupt market present posit phase
data good safeti howev filgotinib face headwind fda requir
complet male testicular safeti studi manta trial gilead/galapago
file approv third tnf-alpha inhibitor like humira face biosimilar entri
could potenti price jak inhibitor view ra market get
competit olumi face continu uphil commerci climb lilli tri
find market competit ra space
figur jak inhibitor space ra crowd
mg dose approv us
mg approv eu
studi dose approv
expans beyond ra challeng safeti data like present problem
launch atop dermat lilly/incyt also investig baricitinib moderate-
to-sever atop dermat ad seen posit data
concern safeti issu seen ra prevent widespread usag
ad speak dermatologist usag jak safeti concern like
olumi would limit ad especi safer system altern
dupix expect addit updat ad program balanc year
given safeti baggag olumi unlik differenti among dmard
view without approv higher mg dose us royalti olumi
sale unlik contribut substanti top-lin growth view
drug undifferenti beyond multipl jak inhibitor must compet
tnf-alpha giant like humira biosimilar entri cheaper list price could
pressur olumi end feel challeng drug find place
lucr us market
valu stock
look earlier pipelin enough clinic data assign
inhibitor oral review latest clinic
pre-clin data program gener expect what next
overal think oral inhibitor could promis
oral earli develop novarti right inhibitor
parsaclisib second-gener inhibitor could potenti use treat
b-cell malign although dlbcl/nhl indic discontinu
concern class inhibitor limit commerci success gilead
zydelig verastem copiktra owe poor clinic profil copiktra
recent approv path approv long difficult infin origin
develop limit clinic data hard us much confid asset
abstract publish blood accept februari link describ asset
object respons rate encourag long-term toler observ studi warrant
investig nhl subtyp hardli enough us assign signific
valu highlight june analyst day ask dlbcl program
stop compani indic respons rate low
viabl therapeut dlbcl compani believ show drug activ
disagre need robust evid fulli board need
concret evid help us better understand activ parsaclisib alon
combin variou therapeut
data citadel trial expect per earli updat
previous potenti read out r/r follicular lymphoma fl margin zone
lymphoma mzl r/r mantl cell lymphoma mcl figur overview
citadel program
cr rate durat respons
cr rate durat respons
cr rate durat respons
capmatinib partner novarti demonstr interest efficaci nsclc non-
small cell lung cancer esmo notabl saw high orr treatment-
nave treatment-experienc patient advanc nsclc patient
skip mutat geori trial link data
encourag could support initi approv note licens
right novarti would elig mileston royalti payment
potenti sale incyte/novarti disclos plan file fda approv
european japanes regulatori file shortli follow view
asset may like win regulatori approv stake econom limit
owe licens novarti expect addit updat either
data present immatur
meant compet merck keytruda bristol opdivo
rather option use conduct combin studi
initi clinic data present june noth special profil
typic howev compani develop asset mono-therapi msi-high
endometri cancer merkel cell carcinoma anal cancer podium program see
figur note provid poc data make
program feel like me-too approach vs innov develop expect
monotherapi data begin msi-high endometri cancer merkel cell
carcinoma anal cancer
like idea in-hous combin trial note
littl clinic data either combin monotherapi opt exclud
asset valuat current work intern combin arginas
axl/mer inhibitor compani referenc previous would like
much clariti program move forward advanc develop
assign valu
econom asset licens deal
paid ww right develop commerci asset
indic elig receiv potenti develop
regulatori mileston potenti commerci mileston royalti rate
rang futur sale asset
aggress cancer
msi-rel diseas
may requir
prognosi current
cancer hpv hiv
interest vs prospect oral avail
preclin data provid suggest profil compar anti-
mab see figur gener prefer vs mab
owe believ better efficaci target receptor vs ligand
oral option could still interest success later-stag clinic develop
late began first-in-human trial clinicaltri gov link
potenti data estim need see clear develop plan
clinic data patient ascrib valu asset
charl martineau univers toronto figur pre-clin data inhibitor
overal think interest earli pipelin focus
itacitinib pemigatinib topic ruxolitinib think meaning posit updat
program could provid upsid share exclud much
formal valuat seen enough compel clinic data fairli includ
dcf assess
forecast incom statement balanc sheet statement cash flow
project fy revenu forecast non-
ep figur incom statement
balanc sheet found figur statement cash flow found
total product sale
total product sale
total product sale
total product sale
profit loss tax
weight average share use calcul dilut ep
jakavi ruxolitinib royalti novarti eu
olumi baricitinib royalti lilli us eu
gross margin product sale
oper margin product sale
net margin product sale
cash equival
prepaid expens current asset
properti equip net
intang asset goodwil
commit conting
accumul comprehens loss
charl martineau univers toronto figur incyt statement flow
statement flow
in-process research develop impair
expens senior note convers
unreal loss long term invest
chang fair valu acquisition-rel conting consider
excess tax provis benefit stock base compens
chang asset liabil
prepaid expens asset
net cash use oper activ
acquisit busi net
purchas market secur
sale matur market secur
net cash use invest activ
proce issuanc common stock plan
proce issuanc common stock net
excess tax provis benefit stock base compens
repurchas convert senior note
net cash use financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
cs peer relationship incyt
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag figur
figur cs peer relationship map
author report evan seigerman would like acknowledg work
matthew terwelp md adrian garcia associ credit suiss large-cap
gvhd immunolog reaction occur patient receiv hematopoiet stem
cell transplant hsct anoth person allogen transplant hsct treat wide
array hematolog malign includ leukemia myelodysplast syndrom
myeloma lymphoma sometim cur option patient
diseas gvhd immun cell primarili cell non-ident donor
graft recogn cell patient host foreign begin attack
patient cell patient commonli develop skin gi liver
manifest importantli caus reject hsct graft potenti
death one-year transplant mortal match donor jagasia et al risk
factor develop gvhd includ increas age gender dispar donor
recipi male femal femal male sourc hsct bone marrow
peripher blood greater risk vs umbil cord blood
antigen match effort taken match donor patient decreas risk
graft reject match process find donor similar human leukocyt
antigen hla hla cellular marker help immun system recogn self
non-self gener everi patient uniqu set hla marker
except ident twin close rel commonli similar hla
make-up hla divid two group major histocompat complex mhc class
mhc class ii mhc class marker found nucleat cell includ hla-
-b -c mhc class ii found mainli immun cell includ hla-dq -dr
dp accord uptod import loci unmatch donor develop
gvhd dissimilar hla-a -b -dr unmatch poorli match donor
usual develop gvhd mismatch mhc gvhd close match donor
typic differ minor histocompat complex loci
acut vs chronic gvhd tradit differ acut day
chronic day gvhd defin onset symptom modern effort
nih link manuscript differenti two clinic symptom due
irregular symptom onset acut gvhd result classic maculopapular rash
abdomin cramp high volum diarrhea
hyperbilirubinemia chronic gvhd characterist skin lesion includ lichen
planu manifest scleroderma gastrointestin ulcer rise bilirubin
level subtyp experi liver abnorm includ liver enlarg
hepatomegali increas alkalin phosphatas dark urin skin itch pruritu
secondari hyperbilirubinemia gastrointestin symptom either subtyp believ
bacteri transloc enhanc stimul toll-lik receptor tlr
caus macrophages/monocyt cell activ via increas cytokin releas
activ cell prolifer releas varieti pro-inflammatori cytokin
host cell via fas-ligand induc apoptosi program cell death perforin-
treatment gvhd grade gvhd defin skin rash bodi surfac area
liver gastrointestin involv grade acut chronic gvhd treat
topic steroid first-lin treatment acut chronic gvhd grade ii greater
glucocorticoid methylprednisolon patient respons steroid
within first seven day defin steroid-refractori cyclosporin tacrolimu
ad glucocorticoid popul jakafi ruxolitinib target patient
gvhd grade ii-iv steroid refractori patient itacitinib target grade ii-iv gvhd
charl martineau univers toronto figur treatment gvhd grade
acut
standard care exist
higher averag leukopenia
worsen renal insuffici
tacrolimu
accord uptod consensu guidelin support use glucocorticoid first-
line treatment gvhd current consensu exist support particular second-lin
therapi host option use treat gvhd see figur vari
efficaci side effect avail data direct comparison exist current
herv hoppenot presid chief execut offic
mr hoppenot director januari appoint chairman board
may serv presid novarti oncolog novarti pharmaceut
corpor us subsidiari novarti ag pharmaceut compani januari
januari prior serv execut posit novarti
pharmaceut corpor serv septemb januari execut
vice presid chief commerci offic novarti oncolog head global product
strategi scientif develop novarti pharmaceut corpor
septemb senior vice presid head global market novarti
oncolog prior join novarti serv variou increasingli senior role
aventi formerli rhnepoulenc pharmaceut compani includ vice
presid oncolog us aventi pharmaceut inc vice
presid us oncolog oper rhonepoulenc rorer pharmaceut inc
hold diploma essec intern busi school mr
hoppenot also director cellecti
dr dhanak join decemb prior join dr dhanak serv
vice presid head discoveri scienc janssen research develop llc
wholly-own subsidiari johnson johnson pharmaceut compani
novemb prior
tenur janssen spent year
glaxosmithklin pharmaceut compani posit increas respons
across multipl diseas area includ last posit vice presid head
cancer epigenet discoveri perform unit receiv chemistri
univers manchest institut scienc technolog ph
univers london complet postdoctor research natur product synthesi
northwestern univers
barri flannelli execut vice presid gener manag us
dr flannelli join execut vice presid busi develop
strateg plan august prior join serv chief execut
offic oss healthcar inc biotechnolog start-up compani august
juli serv vice presid global product strategi commerci plan
nektar therapeut biopharmaceut compani april april
senior vice presid commerci onyx pharmaceut
biopharmaceut compani august januari prior thereto dr
flannelli held key posit biopharmaceut pharmaceut compani
abraxi bioscienc inc novarti dr flannelli earn doctor pharmaci
univers maryland school pharmaci master degre busi
administr univers baltimor degre pharmaci
massachusett colleg pharmaci
prior join april april presid genoptix
corpor decemb march vice presid rare
diseas franchis head novarti oncolog juli decemb
vice presid oncolog gener manag novarti greec octob
global brand execut director novarti
pharmaceut januari octob global brand
director oncolog novarti pharmaceut dr iyengar receiv degre
biolog stanford univers earn harvard medic school
iyengar execut vice presid global strategi corpor
june
maria pasqual execut vice presid gener counsel
ms pasqual join april join celgen corpor
year held posit increas level respons includ chief
counsel senior vice presid legal deputi gener counsel assist corpor
secretari recent execut vice presid global chief complianc offic
prior tenur celgen spent decad support pharmaceut client
global patent litig attorney penni edmond llp new york
career law assist research scientist institut basic research
spring harbor laboratori ms pasqual hold brooklyn law
school biochemistri state univers new york stoni brook
christiana stamouli execut vice presid chief offic
ms stamouli join februari prior join serv
presid februari januari chief financi offic januari
januari inc biopharmaceut compani
januari join ms stamouli independ advisor
biopharmaceut compani decemb senior vice
presid corpor strategi busi develop vertex pharmaceut
inc biopharmaceut compani prior join vertex spent nearli year
invest bank manag consult industri manag
director invest bank divis prior senior
invest banker healthcar invest bank group goldman sach co
spent major invest bank career start career
strategi consult boston consult group ms stamouli hold two
undergradu degre massachusett institut technolog mit
 mit sloan school manag
steven stein execut vice presid chief medic offic
dr stein join senior vice presid chief medic offic march
prior join may februari senior vice presid
us clinic develop medic affair novarti pharmaceut februari
april dr stein vice presid global oncolog clinic develop
head medicin develop hematolog support care
glaxosmithklin held post-doctor fellowship hematology/oncolog
univers pennsylvania earn univers
witwatersrand johannesburg south africa
ms swain join senior vice presid human resourc januari
serv senior vice presid human resourc bristol myer squibb
compani octob januari acquir dupont pharmaceut
compani juli octob senior vice presid human
resourc octob juli held varieti
human resourc posit increas respons ms
swain receiv psycholog industri relat rockhurst univers
wenq yao execut vice presid head discoveri chemistri
dr yao join director chemistri februari held role increas
respons prior join held scientif research posit
dupont pharmaceut bristol myer squibb compani
receiv chemistri xuzhou normal univers organ
chemistri nankai univers ph organic/medicin chemistri
univers pennsylvania
compani mention price
